Robert Blum: Yes. I don’t think the disease burden here is defined by mortality incidents as much as symptom burden and other matters that read on functional life and quality of life. And it’s very clear that patients who receive a cardiac myosin inhibitor are very adherent and compliant with their therapy. Look at the data for Camzyos – these are patients who are benefiting substantially from receiving a new therapy and want to stay on that therapy. And I do believe that, that’s ultimately going to be defining on what could be the opportunity for category expansion. Andrew, anything you want to add to that?
Andrew Callos: Yes. I would say that’s probably part of the remit of what we’re doing in AQR. If you think about some of the secondary end points like improvement in New York Heart Class Association improvement in KCCQ, reduction for the need of septal therapy, and surgery, all those speak to improvement in health outcomes and improvement in cost savings. So I think you’ll start to see some more publications and us talking to that and then merging that with large data sets to show the impact it can have on larger populations. So it may be not as obvious as something as [STTR], but it’s certainly something I think you’re going to see over time that the expertise that we have in ATO around this area will certainly lead to what you’re describing.
Operator: Thank you. And our next question will come from Sean McCutcheon from Raymond James. Your line is open.
Robert Blum: Hello Sean.
Sean McCutcheon: Hi guys. Hi Robert. Thanks for squeezing me in. Can you comment on the patients you will enroll in the Phase 2 study for 586 — or maybe what subset do you think has the clearest capital physiologic rationale and how you’re thinking about the Phase 2 in terms of parsing the HFpEF subsets and maybe broad strokes on the size of the opportunity in those restrictive populations? Thanks.
Fady Malik: Yes. Sure. I’ll ask Stuart to answer that, but in sort of general terms, I’ll just mention ahead of time that as Robert said earlier, the NHCM patients that responded so well in the Phase 2 study kind of provide a human model of the type of HFpEF patients we want to study with CK-586, and maybe Stuart can expand on those characteristics generally.
Stuart Kupfer: Yes. Thanks, Fady. I think that’s right. We believe that for a subgroup of patients with severe diastolic dysfunction may be in large part driven by patients with hypercontractility and some of these patients developed ventricular wall thickening just like patients with non-obstructive HCM. And so the outcome in patients we serve in Phase 2 and the REDWOOD-HCM, but nonobstructive HCM really reads – informs potential benefit and improvement of diastolic function – in the subgroup of patients with HFpEF. And so we’ll be looking – we’ll be evaluating patients who have a relatively high ejection fraction, some degree of ventricular wall thickening — who were symptomatic and having functional and symptomatic heart failure symptoms related to their disease to see those patients could benefit from treatment. So that’s generally the optimation we’ll be targeting.
Robert Blum: Andrew, do you want to speak in general terms approximately around how we’re thinking about the subsets of HFpEF from a prevalence standpoint? Andrew, you might be on mute.
Andrew Callos: Yes. HFpEF just all probably from our press releases around half of the overall market. We’re describing here is a subset of HFpEF in the upper range of ejection fraction. And I think once we start to learn more in Phase 2, we’ll probably hone in more of exactly the size of that subset where the cutoff is.
Sean McCutcheon: Thank you.
Operator: Thank you. And I am showing no further questions from our phone lines. I’d now like to turn the conference back to Robert Blum, President and CEO, for closing remarks.
Robert Blum: Thank you, operator, and thank you to the analysts for some excellent questions. We’re excited to have shared this update with you, especially as it pertains to our expanded focus on the development program for aficamten. And at the same time, we believe that we’re being good financial stewards, as we think about capital diversification and capital deployment and efficiencies. And we’re looking forward to updating you on continued progress including with our presentations next week, Monday, May 13 at the European Heart Failure meetings and afterwards. We thank you for your interest in Cytokinetics and we’ll look forward to the next earnings call. Operator, with that, we can now conclude the call.
Operator: Thank you. This concludes today’s conference call. Thank you for your participation. You may now disconnect.
